Pliant Therapeutics ernennt Craig Blanchette zum Senior Vice President für siRNA-Forschung

• Pliant Therapeutics hat Craig Blanchette zum Senior Vice President, Research (siRNA), ernannt, um die integrinvermittelte Wirkstofftransportplattform voranzutreiben.
• Blanchette war zuletzt Chief Scientific Officer bei Switch Therapeutics und brachte dort zwei Programme bis in IND-vorbereitende Studien.
• Zuvor leitete er bei Genentech die Proteinchemie und verantwortete die Strategie für den Transport von Oligonukleotiden.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200830PRIMZONEFULLFEED9849140) on October 20, 2026, and is solely responsible for the information contained therein.